This is the thought which comes to mind when we read this news today about Biocon also being pulled by the ‘villain’ of Indian pharma companies – the U.S. Food and Drug Administration (U.S. FDA). The stock was down today as its Bengaluru unit has received ten observations on Form 483 by the FDA. This ranges right from nonconformity to procedures and lack of trained and skilled employees